1
|
Oft M, Ratti N, Vivona S, Emmerich J, Riener R, Koliesnik IO, McCauley S, Bauer M, Semana M, Rokkam D, Jayaraman B, Malefyt RDW, Aspuria PJ, Totagrande M, Mehta-Damani A, Lupardus PJ, Kastelein RA. Abstract 1801: STK-012, an a/b-selective IL-2 activates tumor antigen specific CD25+ CD8 T cells to reject tumors without acute vascular toxicity. Cancer Res 2023. [DOI: 10.1158/1538-7445.am2023-1801] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/07/2023]
Abstract
Abstract
High-dose Interleukin-2 (IL-2) monotherapy induces complete responses in cancer patients but its use is limited by acute vascular toxicities including capillary leak syndrome and severe hypotension 1,2. IL-2 activates lymphocytes and NK-cells through the intermediate-affinity dimeric IL-2 receptor, IL-2Rβ/γ (CD122/CD132), while antigen activated T-cells and regulatory T-cells (Tregs) have increased sensitivity to IL-2 by expressing the high-affinity trimeric IL-2 receptor, IL-2Rα/β/γ (CD25/CD122/CD132)3. CD25-independent IL-2s (“non-α-IL-2s”) aim to increase the therapeutic efficacy of IL2 in cancer patients by avoiding Treg activation through selective binding to IL-2Rβ/γ 4. However, those molecules still are reported to induce fever and hypotension and have limited efficacy as a monotherapy or in combination with anti-PD-1 5,6. Here we show that a novel α/β-IL-2 agonist that was designed to preferentially bind to the IL-2Rα/β/γ receptor highly upregulated on antigen activated T-cells can greatly improve on the efficacy of IL-2 while avoiding the vascular toxicity commonly associated with IL-2 treatment. In syngeneic tumor models, this α/β-IL-2 agonist significantly reduced exhaustion of tumor infiltrating T cells compared to WT-IL-2 or a non-α-IL-2 leading to improved expansion of tumor antigen specific CD25+PD-1+CD8+ T cells systemically and in the tumor microenvironment. This resulted in complete responses and tumor immune memory with α/β-IL-2 monotherapy as well as improved outcomes in combination with anti-PD-1 therapy in PD-1 refractory syngeneic tumors. In contrast, WT-IL-2 reduced T cell exhaustion and drove antigen specific T cell responses to a lesser degree, resulting in reduced combinatorial efficacy with anti-PD-1, while the non-α-IL-2 failed to do either. Furthermore, the α/β-IL-2 agonist reduced intratumoral Tregs compared to treatment with WT-IL-2 or PBS improving the intratumoral CD8 to Treg ratio. In non-human primates and mice, WT-IL-2 and a non-α-IL-2 led to broad extravasation of lymphocytes and NK cells and activation of intra-pulmonal T cells resulting in systemic tissue inflammation and NK cell-mediated lethal capillary leak syndrome whereas the α/β-IL-2 agonist, which avoids binding the dimeric IL-2Rβ/γ expressed on NK cells, avoided systemic lymphocyte activation which facilitated continuous treatment without acute vascular toxicities. Overall, through selective engagement of CD25+ T cells, this α/β-IL-2 agonist demonstrated improved efficacy and tolerability of IL-2 in preclinical tumor models. Clinical trials with STK-012, a human α/β-IL-2 agonist, are in progress.1 Atkins, et al.; JCO 1999, 2 Dutcher, et al.; JITC 2014, 3 Liao, et al.; Immunity 2013, 4 Levin, et al.; Nature 2012, 5 Janku, et al.; Cancer Research 2021; 6 Diab, et al.; Cancer Disc. 2020
Citation Format: Martin Oft, Navneet Ratti, Sandro Vivona, Jan Emmerich, Romina Riener, Ievgen O. Koliesnik, Scott McCauley, Michele Bauer, Marie Semana, Deepti Rokkam, Bhargavi Jayaraman, Rene de Waal Malefyt, Paul-Joseph Aspuria, Michael Totagrande, Anita Mehta-Damani, Patrick J. Lupardus, Rob A. Kastelein. STK-012, an a/b-selective IL-2 activates tumor antigen specific CD25+ CD8 T cells to reject tumors without acute vascular toxicity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1801.
Collapse
|
2
|
Koliesnik I, Emmerich J, Tran KQ, Bauer M, Totagrande M, Jayaraman B, Buffone C, Balasubrahmanyam P, Rokkam D, Malefyt RDW, Zuniga L, Greb H, Ratti N, Vivona S, Oft M, Lupardus PJ, Kastelein RA. Abstract 1833: Novel IL-12 Partial Agonist For Cancer Immunotherapy Avoids NK-cell Mediated Toxicity. Cancer Res 2023. [DOI: 10.1158/1538-7445.am2023-1833] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/07/2023]
Abstract
Abstract
Here we report on a novel human IL-12 partial agonist (hIL-12v) that has diminished binding to IL-12Rb1. IL-12v is designed to more selectively engage antigen activated T-cells, which strongly upregulate IL-12Rb1 upon activation, and to reduce stimulation of NK cells or resting T cells, which express modest levels of IL-12Rb1. To explore anti-tumor efficacy and toxicity in mouse syngeneic tumor models, we generated a half-life extended mouse surrogate of the IL-12 partial agonist (mIL-12v Fc) and compared it to a similarly engineered half-life extended version of wild type mouse IL-12 (mIL-12wt Fc). At efficacious doses, systemic administration of mIL-12wt Fc induced significant weight loss and lethality characterized by early proinflammatory cytokine release and systemic NK cell activation. Conversely, mIL-12v Fc was well tolerated and avoided the robust and rapid NK cell activation and peripheral NK count decreases seen with mIL-12v Fc, suggestive of extravasation to tissues. Both mIL-12v Fc and mIL-12 WT Fc showed similar robust single-agent anti-tumor efficacy in syngeneic tumor models. Depletion of NK cells did not diminish anti-tumor efficacy. Efficacy for both molecules was characterized by CD8 T cell activation, myeloid cell reprograming and antigen presentation. Moreover, combination of mIL-12v Fc with systemic immunotherapies further enhanced anti-tumor activity without compromising tolerability. Overall, mIL-12v Fc retained anti-tumor efficacy without induction of severe toxicities compared to mIL-12wt Fc. These data suggest IL-12 partial agonists may represent a novel immunotherapy approach to maintain efficacy while avoiding classical toxicity associated with IL-12 therapy.1 Atkins, et al.; (1997) Clinical Cancer Research 3(3):409-172 Carson, et al. (1999) J Immunology 162 (8): 4943-4951.
Citation Format: Ievgen Koliesnik, Jan Emmerich, Kim Q. Tran, Michele Bauer, Michael Totagrande, Bhargavi Jayaraman, Cindy Buffone, Priyanka Balasubrahmanyam, Deepti Rokkam, Rene de Waal Malefyt, Luis Zuniga, Heiko Greb, Navneet Ratti, Sandro Vivona, Martin Oft, Patrick J. Lupardus, Robert A. Kastelein. Novel IL-12 Partial Agonist For Cancer Immunotherapy Avoids NK-cell Mediated Toxicity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1833.
Collapse
|
3
|
Malefyt RDW, Aspuria PJ, Vivona S, Balasubrahmanyam P, Buffone C, Ramadass M, Riener R, Oft M, Lupardus P, Kastelein R. Abstract 4225: IL-2Rβ/IL-2R γsynthetic cytokines induce activation of human T and NK cells. Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-4225] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Heterodimerization of the intermediate affinity Interleukin-2 Receptors (IL-2R), IL-2Rβ and IL-2Rγ, initiates a signaling cascade in T and NK cells that ultimately results in proliferation and production of Interferon-gamma (IFN-γ). Binding of IL-2 in a dimeric complex with intermediate affinity or in the high affinity trimeric complex, which also includes IL-2Rα and is predominantly expressed on antigen activated T cells and Tregs leads to trans-phosphorylation of signaling motifs on the IL-2Rβ and IL-2Rγ intracellular domains by the associated JAK kinases. The function of the wild type IL-2 is to bring the receptor chains in close proximity to produce an optimal level of phosphorylation and activation of associated STAT transcription factors. Here we established a way to bring IL-2Rβ and IL-2Rγ chains together in a cytokine-independent manner that results in functional activation.
Experimental Procedures: Human IL-2Rβ and IL-2Rγ specific heavy chain single domain antibodies (VHH) were generated by camel immunization and screening of VHH libraries prepared from peripheral blood cells for binding. Ten IL-2Rβ VHH segments and six IL-2Rγ VHH segments, all with low nanomolar affinity, were identified and coupled as IL-2Rβ/IL-2Rγ VHH dimers in all possible combinations in both amino-carboxy and carboxy-amino orientations yielding 120 different proteins that were tested in human T and NK cell functional assays.
Results: IL-2Rβ/IL-2Rγ VHH dimers were biologically active and induced pSTAT-5 phosphorylation in the IL-2 dependent NK cell line NKL at various levels. The biological activity of these IL-2Rβ/IL-2Rγ VHH dimers was further confirmed on primary cells. IL-2Rβ/IL-2Rγ VHH dimers induced pSTAT5 phosphorylation on NK cells isolated from human peripheral blood and culture with IL-2Rβ/IL-2Rγ VHH dimers resulted in proliferation and production of high but varied levels of IFN-γ. The activity of IL-2Rβ/IL-2Rγ VHH dimers on primary T cells was also examined. Similar to NK cells, IL-2Rβ/IL-2Rγ VHH dimers induced pSTAT5 phosphorylation, proliferation and IFN-γ production by CD4 positive and CD8 positive T cell blasts generated after CD3/CD28 activation of human PBMC.
Conclusions: In conclusion, we have generated a series of functional IL-2Rβ/IL-2Rγ VHH dimers representing surrogate cytokine agonists each with unique signaling strengths that will now be further analyzed for potential therapeutic application in tumor immunology and auto-immunity
Citation Format: Rene de Waal Malefyt, PJ Aspuria, Sandro Vivona, Priyanka Balasubrahmanyam, Cindy Buffone, Mahalakshmi Ramadass, Romina Riener, Martin Oft, Patrick Lupardus, Robert Kastelein. IL-2Rβ/IL-2R γsynthetic cytokines induce activation of human T and NK cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 4225.
Collapse
|
4
|
Ramadass M, Vivona S, Rokkam D, Greb H, Gangopadhyay A, Riener R, Malefyt RDW, Lupardus P, Oft M, Kastelein R. Abstract 5544: IL10/IL2 surrogate cytokine agonists. Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-5544] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: IL10 is a pleiotropic cytokine that is secreted as a homodimer and initiates signaling on various cell types by engaging two copies of a heterodimeric receptor complex consisting of an IL-10Rα subunit and a IL-10Rβ subunit. IL10 signaling through the natural ligand has both immunosuppressive and immunostimulatory effects and this pleiotropy makes it difficult to develop wild type IL-10 for therapeutic use. In clinical trials that have studied IL10 in cancer, anemia, thrombocytopenia and hemophagocytosis associated with macrophage activation led to dose interruption and dose reduction. To drive more selective cytokine signaling only on cells of interest, we have generated surrogate cytokine agonists that bind to IL10Rα and IL2Rγ, resulting in the selective activation of T cells over macrophages. We establish a novel means of bridging the IL10Rα and IL2Rγ receptors using a IL10Rα/IL2Rγ surrogate cytokine agonist that consists of a domain that binds to IL10Rα and a second domain that binds to IL2Rγ. Upon contact with a cell that allows bridging of IL10Rα and IL2Rγ, the surrogate cytokine agonist causes the functional association of IL10Rα and IL2Rγ, resulting in downstream signaling in select cell types.
Experimental Procedures: Human IL-10Rα and IL-2Ry specific single domain VHHs were generated by camel immunization and screening of VHH libraries prepared from peripheral blood cells for binding. Seven IL-10Rα VHHs and six IL-2Ry VHHs were identified and coupled as IL10Rα/IL2Ry dual VHHs in an all by all matrix and in both amino-carboxy and carboxy-amino orientations, yielding 84 unique surrogate cytokine agonists. These surrogate cytokine agonists were screened on a (p)STAT3 assay on primary human cells and further tested in T cell and monocyte functional assays.
Results: Several IL10Rα/IL2Rγ surrogate cytokine agonists were biologically active on primary human lymphoid cells, inducing (p)STAT3 signal in B cells, NK cells, CD4 and CD8 T cells with little to no (p)STAT3 signal in monocytes. These IL10Rα/IL2Rγ surrogate cytokine agonists were also functionally active in promoting cell survival and at inducing IFN-γ and Granzyme production by CD8 T cell blasts generated upon CD3/CD28 activation. Consistent with the lack of STAT3 signaling in monocytes, the IL10Rα/IL2Rγ surrogate cytokine agonists did not inhibit LPS induced secretion of IL1β and TNFα by monocytes, suggesting selectivity and a lack of immunosuppressive activities.
Conclusions: Designing surrogate cytokine agonists that pair non-natural cytokine receptors provides the possibility of generating molecules that can decouple the pleiotropy of cytokines like IL10 by stimulating only the desired cell population. Here, we have generated IL10Rα/IL2Rγ surrogate cytokine agonists that are biologically active and signal with varying strengths in the lymphoid cells with little to no activity on monocytes, thus providing an opportunity to decouple the pleiotropy of IL10 for use in cancer therapy.
Citation Format: Mahalakshmi Ramadass, Sandro Vivona, Deepti Rokkam, Heiko Greb, Anu Gangopadhyay, Romina Riener, Rene de Waal Malefyt, Patrick Lupardus, Martin Oft, Robert Kastelein. IL10/IL2 surrogate cytokine agonists [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5544.
Collapse
|
5
|
Aspuria PJ, Semana M, Vivona S, Ramadass M, Ratti N, Riener R, Bauer M, Ali M, Rokkam D, Kastelein RA, Lupardus PJ, Oft M. Abstract 2824: Engineered human IL-2/IL-2Rb orthogonal pairs selectively enhance anti-GPC3 CAR T cells to drive complete responses in solid epithelial tumor models. Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-2824] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
CAR T cell therapy has demonstrated clinical efficacy against hematological malignancies. However, prominent barriers including poor T cell effector function, lack of proliferation, and limited CAR T cell persistence have prevented CAR T cell therapies from reaching their full curative potential, especially in solid tumors. Interleukin-2 (IL-2) is a potent stimulator of T cell proliferation, survival, and cytotoxic function, thereby making it an attractive cytokine to support CAR T cell therapy. However, therapeutic use of IL-2 is limited by systemic toxicity due its promiscuous activation of undesired immune cell populations, including non-tumor reactive T cells and NK cells.
To facilitate selective ex vivo and in vivo expansion of engineered T cells we have developed a human orthogonal (ortho) ligand/receptor system consisting of a IL-2 mutein (STK-009) that does not significantly stimulate cells expressing wild type IL-2 receptor and a mutated IL-2 Receptor Beta (orthoIL-2Rβ) that responds to STK-009 but not wild type IL-2. This system enables in vivo IL-2 signaling in engineered cells that express the orthoIL-2Rβ while avoiding stimulation of native T cells and NK cells. Previously, we demonstrated the ability of the STK-009/orthoIL-2Rβ receptor pair to selectively enhance the anti-tumor efficacy of orthoIL-2Rβ (hoRb) expressing CD19 CAR T cells (SYNCAR-001) in preclinical lymphoma mouse models. We also demonstrated that STK-009 is selective for the orthoIL-2Rβ expressing cells and therefore in a non-human primate model does not stimulate native T or NK cells.
Here, we demonstrate the ability of the STK-009/hoRb system to enhance the anti-tumor activity and persistence of anti-glypican 3 (GPC3) CAR T cells. GPC3 overexpression is associated with various malignancies such as hepatocellular carcinoma (HCC), pediatric sarcomas, and non small cell lung carcinoma (NSCLC). Clinical trials of GPC3 CAR T therapy are ongoing, but early data suggests a need to boost CAR T cell function and persistence to achieve significant clinical responses. We incorporated the hoRb downstream of an anti-GPC3_28z CAR via a T2A cleavage peptide (SYNCAR-002). In vivo, STK-009 administration enhanced the anti-tumor efficacy of SYNCAR-002 in highly aggressive subcutaneous and intraperitoneal HCC models. STK-009 treatment resulted in significant expansion of SYNCAR-002 and drove infiltration of SYNCAR-002 into tumors. STK-009 treatment also induced intratumoral granzyme B+ and IFN-γ+ production by SYNCAR-002 indicating activation of effector T cell function.
These findings validate that the orthogonal IL-2 platform has the potential to improve the efficacy and durability of CAR T therapy for solid tumor targets such as GPC3 by selectively expanding CAR-T cells in vivo, driving CAR-T cells into the tumor, and activating CAR-T cells in the tumor microenvironment.
Citation Format: Paul-Joseph Aspuria, Marie Semana, Sandro Vivona, Mahalaksmi Ramadass, Navneet Ratti, Romina Riener, Michele Bauer, Mohammed Ali, Deepti Rokkam, Rob A. Kastelein, Patrick J. Lupardus, Martin Oft. Engineered human IL-2/IL-2Rb orthogonal pairs selectively enhance anti-GPC3 CAR T cells to drive complete responses in solid epithelial tumor models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2824.
Collapse
|
6
|
Kochel C, Sun M, Ratti N, Vivona S, Ramadass M, Semana M, Bauer M, Ali M, Emmerich J, Kastelein R, Lupardus PJ, Aspuria PJ, Oft M. Abstract 586: Orthogonal IL-2/IL-2RB signaling in adoptively transferred T cells controls tumor growth without the need for lymphodepletion in a B16 tumor model. Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-586] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Multiple adoptive T-cell therapy modalities (ACT) have delivered promising clinical responses in cancer patients. However, challenges including poor T cell effector function, lack of proliferation, and limited persistence have prevented ACTs from reaching their full curative potential. In addition, ACTs typically require lymphodepletion to aid cell engraftment. Lymphodepletion has been shown to improve persistence and efficacy of ACTs by elevating T-cell common gamma-chain cytokines like IL-7 and IL-15. However, lymphodepletion regimens have been identified as a risk factor for cytokine release syndrome (CRS) and infectious complications from opportunistic pathogens. IL-2, another common gamma-chain cytokine, is a potent stimulator of T cells, making it an attractive cytokine to support ACT and potentially bypass the need for lymphodepletion. However, therapeutic use of IL-2 is limited by systemic toxicity due its promiscuous activation of immune cells.
To facilitate selective delivery of an IL-2 signal to engineered T cells and avoid signaling in bystander T cells and NK cells, we developed a mouse orthogonal receptor/ligand system consisting of a mutated IL-2 Receptor Beta (moRβ) and a pegylated, IL-2 mutein (moIL-2) that does not significantly activate the wild type IL-2β receptor but does activate moRβ. T cells from pmel-1 T cell receptor-transgenic mice, recognizing gp100 on B16 melanoma cells were transduced with moRβ (orthoPmel). A highly active moIL-2 was continuously dosed for four weeks in mice. Thy1.1+ orthoPmel T cells were tracked by FACS and IHC systemically and in the tumor.
During orthoPmel manufacturing, moIL-2 specifically enriched orthoPmel compared to mouse WT IL-2. OrthoPmel in combination with moIL-2 controlled tumor growth in lymphoreplete mice bearing established B16 tumors while neither component alone inhibited tumor growth. moIL-2 significantly expanded orthoPmel systemically and intratumorally, with orthoPmel ultimately accounting for greater than 80% or 40% of all peripheral and intratumoral T cells, respectively. Systemic orthoPmel maintained a consistent central memory and effector memory mix throughout the four-week moIL-2 treatment course. moIL-2 also induced the expression of activation markers, CD25 and Granzyme B, in intratumoral orthoPmel.
These findings validate than an orthogonal IL-2/IL-2Rβ platform can enhance efficacy of ACTs without peripheral expansion or activation of NK cells or non-tumor specific T cells and the toxicities typically associated with high dose IL-2 therapy. Importantly, these results demonstrate the potential of this platform overcome the requirement of lymphodepletion in adoptive cell therapies.
Citation Format: Christina Kochel, Meng Sun, Navneet Ratti, Sandro Vivona, Mahalaksmi Ramadass, Marie Semana, Michele Bauer, Mohammed Ali, Jan Emmerich, Rob Kastelein, Patrick J. Lupardus, Paul-Joseph Aspuria, Martin Oft. Orthogonal IL-2/IL-2RB signaling in adoptively transferred T cells controls tumor growth without the need for lymphodepletion in a B16 tumor model [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 586.
Collapse
|
7
|
Aspuria PJ, Vivona S, Bauer M, Semana M, Ratti N, McCauley S, Riener R, de Waal Malefyt R, Rokkam D, Emmerich J, Kastelein RA, Lupardus PJ, Oft M. An orthogonal IL-2 and IL-2Rβ system drives persistence and activation of CAR T cells and clearance of bulky lymphoma. Sci Transl Med 2021; 13:eabg7565. [PMID: 34936383 DOI: 10.1126/scitranslmed.abg7565] [Citation(s) in RCA: 32] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
[Figure: see text].
Collapse
|
8
|
Emmerich J, Bauer M, Semana M, Jayaraman B, Vivona S, McCauley S, Riener R, Malefyt RDW, Aspuria PJ, Rokkam D, Lupardus P, Kastelein R, Oft M. Abstract 1744: STK-012, an alpha/beta selective IL-2 mutein for the activation of the antigen-activated T cells in solid tumor. Cancer Res 2021. [DOI: 10.1158/1538-7445.am2021-1744] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Interleukin-2 (IL-2) is a potent stimulator of T and NK cell proliferation, survival, and cytotoxic function. High dose IL-2 induces complete responses as a single agent in certain cancers. Its use is limited due to toxicities such as severe hypotension and vascular leak syndrome (VLS). A better understanding of the mechanisms of IL-2 efficacy and toxicity and development of more selective therapies are needed to improve the use of IL-2. Next generation IL-2 therapeutics have been engineered to bias activity towards the dimeric form of the IL-2 receptor, which consists of IL-2Rβ (CD122) and IL-2Rγ (CD132), and away from the high affinity trimeric form of the receptor, which also includes IL-2Rα (CD25). This approach is designed to stimulate NK cells and naïve effector T-cells, which express the dimeric, and not the trimeric, form of the receptor. However, this approach largely misses antigen-activated and tumor-specific T-cells, which have high expression of both CD25 and CD122. In addition, this approach expands peripheral NK cells, which have been shown in mice to cause VLS (1-3).To specifically stimulate antigen-activated CD25+ effector T cells in cancer patients and avoid systemic NK and naïve T cell activation, we have developed a PEGylated, CD25/CD122-selective IL-2 mutein (STK-012) and its mouse surrogate (STK-014). Here we present efficacy and safety of STK-014 compared to wild type IL-2 (wtIL-2) and a CD122/CD132 biased IL-2 (βγIL-2). We also present safety of STK-012 in non-human primates (NHP). STK-012/STK-014 selectively induced STAT5 phosphorylation and proliferation in antigen activated T cells but not in NK cells and naïve T cells. In mice, STK-014 showed reduced toxicity compared to wtIL-2 and βγIL-2. In particular, wtIL-2 and βγIL-2 induced VLS while STK-014 did not. Moreover, STK-014 demonstrated complete responses both as single agent and in combination with a PD-1 antibody in syngeneic tumor models. In general, STK-014 demonstrated improved efficacy compared to wtIL-2 and βγIL-2. STK-014 dramatically increased intratumoral T cells and intratumoral cytotoxic activity compared wtIL-2 and βγIL-2 while avoiding T cell activation in the spleen. STK-014 treatment drastically increased the CD8+ T cell to Treg ratio within the tumor when compared to control tumors (25-fold), but also in comparison to wtIL-2 (2.75-fold) and to βγIL-2 (5.2-fold).In NHP, STK-012 was well tolerated at doses supra-efficacious in mice. Weekly dosing of STK-012 led to continuous elevated serum concentrations, demonstrating selectivity for CD25/122+ T cells. STK-012 selectively induced memory T cell expansion, including CD28+ CD95+ CD8 T cells. In summary, STK-012 avoids IL-2 mediated toxicity and may enable the specific expansion of antigen activated memory T cells in cancer patients, leading to durable tumor response. 1 Peace DJ and Cheever MA. JEM, 1989.2 Gatley MK et al. JI, 1988.3 Assier E et al. JI; 2004.
Citation Format: Jan Emmerich, Michele Bauer, Marie Semana, Bhargavi Jayaraman, Sandro Vivona, Scott McCauley, Romina Riener, Rene De Waal Malefyt, Paul-Joseph Aspuria, Deepti Rokkam, Patrick Lupardus, Rob Kastelein, Martin Oft. STK-012, an alpha/beta selective IL-2 mutein for the activation of the antigen-activated T cells in solid tumor [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 1744.
Collapse
|
9
|
Aspuria PJP, Vivona S, Bauer M, Semana M, Ratti N, McCauley S, Riener R, Malefyt RDW, Rokkam D, Emmerich J, Lupardus PJ, Kastelein RA, Oft M. Abstract 1512: OrthoCARs: Engineered human IL-2/IL-2Rb orthogonal pairs selectively enhance CAR T cell antitumor efficacy by driving T cell expansion and fitness. Cancer Res 2021. [DOI: 10.1158/1538-7445.am2021-1512] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
CAR T cell therapy (CAR) has demonstrated remarkable clinical efficacy in hematological malignancies. However, barriers such as poor T cell effector function, lack of proliferation, and limited persistence prevent CARs from reaching their full curative potential. IL-2 is a potent stimulator of T cell proliferation, survival, and cytotoxic function, making it an attractive cytokine to support CARs. However, therapeutic use of IL-2 is limited by systemic toxicity due its promiscuous activation of undesired immune cell populations.
To facilitate selective expansion and activation of CARs we have developed a human orthogonal ligand/receptor system consisting of a pegylated IL-2 mutein (STK-009) that does not significantly activate the wild type IL-2 receptor and a mutated IL-2 Receptor Beta (hoRb) that is fully activated by STK-009, but does not respond to the native IL-2 ligand. This system enables in vivo IL-2 signaling in CARs engineered to express hoRb while avoiding signaling bystander T cells and NK cells. Here, we demonstrate the ability of the STK-009/hoRb receptor pair to selectively enhance the anti-tumor efficacy of hoRb expressing CD19 CARs (SYNCAR-001) in preclinical lymphoma mouse models at will. We also demonstrate, in non-human primates (NHP), that STK-009 is selective for hoRb expressing cells.
SYNCAR-001 + STK-009 can lead to complete responses in subcutaneous Raji mouse models, even with SYNCAR-001 dosed at sub-efficacious levels (400,000 CAR-Ts/mouse). Subcutaneous dosing of STK-009 expands SYNCAR-001 systemically and drives infiltration of SYNCAR-001 into tumors. UMAP analysis of STK-009 treated SYNCAR-001 reveal a small PD1+LAG3+ subpopulation during tumor rejection which disappeared once tumors are controlled. The majority of T cells showed no exhaustion markers. Further, an IL-7R+ population arises and remains after tumor control, indicating long term memory development. Nanostring analysis confirms upregulation of IL-7R and other critical genes involved in cytotoxic activity and persistence in SYNCAR-001 when treated with STK-009. These data demonstrate that STK-009 treatment expands SYNCAR-001 and delivers a gene signature indicative of enhanced T cell fitness and activity.
Subcutaneous administration of STK-009 in NHP shows no evidence of toxicity or physiological IL-2 mediated activity on immune cells, including Teffs, Tregs, and NK cells. Pharmacokinetic analysis of STK-009 shows stable exposure with minimal clearance, demonstrating the selectivity of STK-009.
These findings validate an orthogonal platform that selectively drives potent T cell effector functions of engineered cells without the toxicities mediated by NK cells or non-tumor specific T cells associated with high dose IL-2 therapy. These results demonstrate the ability of this orthogonal platform to improve the efficacy and durability of CARs.
Citation Format: Paul-Joseph P. Aspuria, Sandro Vivona, Michele Bauer, Marie Semana, Navneet Ratti, Scott McCauley, Romina Riener, Rene de Waal Malefyt, Deepti Rokkam, Jan Emmerich, Patrick J. Lupardus, Rob A. Kastelein, Martin Oft. OrthoCARs: Engineered human IL-2/IL-2Rb orthogonal pairs selectively enhance CAR T cell antitumor efficacy by driving T cell expansion and fitness [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 1512.
Collapse
|
10
|
Hayashi K, Longenecker KL, Liu YL, Faust B, Prashar A, Hampl J, Stoll V, Vivona S. Complex of human Melanotransferrin and SC57.32 Fab fragment reveals novel interdomain arrangement with ferric N-lobe and open C-lobe. Sci Rep 2021; 11:566. [PMID: 33436675 PMCID: PMC7804310 DOI: 10.1038/s41598-020-79090-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2020] [Accepted: 12/01/2020] [Indexed: 01/29/2023] Open
Abstract
Melanotransferrin (MTf) is an iron-binding member of the transferrin superfamily that can be membrane-anchored or secreted in serum. On cells, it can mediate transferrin-independent iron uptake and promote proliferation. In serum, it is a transcytotic iron transporter across the blood-brain barrier. MTf has been exploited as a drug delivery carrier to the brain and as an antibody-drug conjugate (ADC) target due to its oncogenic role in melanoma and its elevated expression in triple-negative breast cancer (TNBC). For treatment of TNBC, an MTf-targeting ADC completed a phase I clinical trial (NCT03316794). The structure of its murine, unconjugated Fab fragment (SC57.32) is revealed here in complex with MTf. The MTf N-lobe is in an active and iron-bound, closed conformation while the C-lobe is in an open conformation incompatible with iron binding. This combination of active and inactive domains displays a novel inter-domain arrangement in which the C2 subdomain angles away from the N-lobe. The C2 subdomain also contains the SC57.32 glyco-epitope, which comprises ten protein residues and two N-acetylglucosamines. Our report reveals novel features of MTf and provides a point of reference for MTf-targeting, structure-guided drug design.
Collapse
Affiliation(s)
- Kristyn Hayashi
- grid.431072.30000 0004 0572 4227Research and Development, AbbVie Inc., South San Francisco, CA 94080 USA
| | - Kenton L. Longenecker
- grid.431072.30000 0004 0572 4227Research and Development, AbbVie Inc., North Chicago, IL 60064 USA
| | - Yi-Liang Liu
- grid.431072.30000 0004 0572 4227Research and Development, AbbVie Inc., South San Francisco, CA 94080 USA
| | - Bryan Faust
- grid.431072.30000 0004 0572 4227Research and Development, AbbVie Inc., South San Francisco, CA 94080 USA
| | - Aditi Prashar
- grid.431072.30000 0004 0572 4227Research and Development, AbbVie Inc., South San Francisco, CA 94080 USA
| | - Johannes Hampl
- grid.431072.30000 0004 0572 4227Research and Development, AbbVie Inc., South San Francisco, CA 94080 USA
| | - Vincent Stoll
- grid.431072.30000 0004 0572 4227Research and Development, AbbVie Inc., North Chicago, IL 60064 USA
| | - Sandro Vivona
- grid.431072.30000 0004 0572 4227Research and Development, AbbVie Inc., South San Francisco, CA 94080 USA
| |
Collapse
|
11
|
Cui L, Vivona S, Smith BR, Kothapalli SR, Liu J, Ma X, Chen Z, Taylor M, Kierstead PH, Fréchet JM, Gambhir SS, Rao J. Reduction Triggered In Situ Polymerization in Living Mice. J Am Chem Soc 2020; 142:15575-15584. [PMID: 32804495 PMCID: PMC8171073 DOI: 10.1021/jacs.0c07594] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
"Smart" biomaterials that are responsive to physiological or biochemical stimuli have found many biomedical applications for tissue engineering, therapeutics, and molecular imaging. In this work, we describe in situ polymerization of activatable biorthogonal small molecules in response to a reducing environment change in vivo. We designed a carbohydrate linker- and cyanobenzothiazole-cysteine condensation reaction-based small molecule scaffold that can undergo rapid condensation reaction upon physiochemical changes (such as a reducing environment) to form polymers (pseudopolysaccharide). The fluorescent and photoacoustic properties of a fluorophore-tagged condensation scaffold before and after the transformation have been examined with a dual-modality optical imaging method. These results confirmed the in situ polymerization of this probe after both local and systemic administration in living mice.
Collapse
Affiliation(s)
- Lina Cui
- Department of Medicinal Chemistry, University of Florida, Gainesville, FL, USA
- UF Health Cancer Center, University of Florida, Gainesville, FL, USA
- Molecular Imaging Program at Stanford, Bio-X Program, Department of Radiology, School of medicine, Stanford University, Stanford, CA, USA
- Department of Chemistry, Stanford University, CA, USA
| | - Sandro Vivona
- Department of Molecular and Cellular Physiology, Stanford University, CA, USA
- Department of Structural Biology, Stanford University, Stanford, CA, USA
- Department of Photon Science, Stanford University, Stanford, CA, USA
| | - Bryan Ronain Smith
- Molecular Imaging Program at Stanford, Bio-X Program, Department of Radiology, School of medicine, Stanford University, Stanford, CA, USA
| | - Sri R. Kothapalli
- Molecular Imaging Program at Stanford, Bio-X Program, Department of Radiology, School of medicine, Stanford University, Stanford, CA, USA
| | - Jun Liu
- Department of Medicinal Chemistry, University of Florida, Gainesville, FL, USA
- UF Health Cancer Center, University of Florida, Gainesville, FL, USA
| | - Xiaowei Ma
- Department of Medicinal Chemistry, University of Florida, Gainesville, FL, USA
- UF Health Cancer Center, University of Florida, Gainesville, FL, USA
| | - Zixin Chen
- Department of Medicinal Chemistry, University of Florida, Gainesville, FL, USA
- UF Health Cancer Center, University of Florida, Gainesville, FL, USA
- Department of Chemistry, Stanford University, CA, USA
| | - Madelynn Taylor
- Molecular Imaging Program at Stanford, Bio-X Program, Department of Radiology, School of medicine, Stanford University, Stanford, CA, USA
| | | | | | - Sanjiv S. Gambhir
- Molecular Imaging Program at Stanford, Bio-X Program, Department of Radiology, School of medicine, Stanford University, Stanford, CA, USA
- Department of Bioengineering, Stanford University, CA, USA
- Department of Materials Science and Engineering, Stanford University, Stanford, CA, USA
| | - Jianghong Rao
- Molecular Imaging Program at Stanford, Bio-X Program, Department of Radiology, School of medicine, Stanford University, Stanford, CA, USA
- Department of Chemistry, Stanford University, CA, USA
| |
Collapse
|
12
|
Aspuria PJ, Bauer M, Vivona S, Kauder SE, McCauley S, Riener R, Malefyte RDW, Ratti N, Rokkam D, Emmerich J, Lupardus PJ, Kastelein RA, Oft M. Abstract 3252: OrthoCARs: Engineered human IL-2/IL-2Rb orthogonal pairs selectively enhance CAR T cell anti-tumor efficacy and durability of response. Cancer Res 2020. [DOI: 10.1158/1538-7445.am2020-3252] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
CAR T cell therapy has demonstrated remarkable clinical efficacy against relapsed and refractory hematological malignancies, such as B cell non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL). Despite these advances, prominent barriers including poor T cell effector function, lack of proliferation, and limited CAR T cell persistence prevent CAR T cell therapies from reaching their full curative potential. Interleukin-2 (IL-2) is a potent stimulator of CD4 and CD8 effector T cell proliferation, survival, and cytotoxic function, thereby making it an attractive molecule to support CAR T cell therapy. However, therapeutic use of IL-2 is limited by systemic toxicity due its promiscuous activation of undesired immune cell populations, including non-tumor reactive T cells and NK cells. To facilitate selective in vivo expansion of engineered T cells we have developed an orthogonal (ortho) ligand/receptor system consisting of a pegylated, IL-2 mutein (STK-009) and a mutated IL-2 Receptor Beta (orthoIL-2Rβ) that selectively bind each another, but do not interact with their wild type receptor and cytokine counterparts. This system allows for in-vivo IL-2 signaling in engineered adoptive cell therapies that express the orthoIL-2Rβ while avoiding signaling in non-tumor reactive T cells and NK cells. Here, we demonstrate the ability of STK-009/orthoIL-2Rβ pair to selectively potentiate human orthoIL-2Rβ expressing CD19 CAR T cells in vitro and in vivo. We incorporated orthoIL-2Rβ into a CD19 directed CAR lentiviral construct utilizing a T2A peptide linker, allowing the use of a single lentiviral plasmid to generate orthoCAR T cells. Transduction of donor T cells with the CAR+orthoIL-2Rβ lentivirus and the use of STK-009 during in vitro manufacturing enabled selective proliferation and enrichment of orthoCAR transduced T cells. orthoCAR T cells grown in STK-009 maintained a similar immunophenotype and cytotoxic function compared to T cells manufactured with wild type IL-2. Subcutaneous administration of STK-009 dramatically enhanced the expansion (>100-fold) and efficacy of orthoCAR T cells in an aggressive pre-clinical mouse model of B cell malignancy (Raji), demonstrating 100% durable complete responses, compared to 50% relapsed and refractory lymphoma in CD19 CAR alone. Immunoprofiling of in vivo orthoCAR T cells revealed that STK-009 treatment significantly increased both naïve and effector memory RA (TEMRA) populations. RNAseq and IHC analysis also showed that STK-009 treatment increases expression of cytotoxic molecules such as Granzyme B and perforin specifically in the CAR T cells, without inducing GranzymeB in other cells. These findings validate a potent platform that selectively harnesses the potent anti-tumoral T cell effector functions of IL-2 to improve the efficacy and durability CAR T cell therapy.
Citation Format: Paul-Joseph Aspuria, Michele Bauer, Sandro Vivona, Steven E. Kauder, Scott McCauley, Romina Riener, Rene De Waal Malefyte, Navneet Ratti, Deepti Rokkam, Jan Emmerich, Patrick J. Lupardus, Rob A. Kastelein, Martin Oft. OrthoCARs: Engineered human IL-2/IL-2Rb orthogonal pairs selectively enhance CAR T cell anti-tumor efficacy and durability of response [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 3252.
Collapse
|
13
|
Hayashi K, Longenecker KL, Koenig P, Prashar A, Hampl J, Stoll V, Vivona S. Structure of human DPEP3 in complex with the SC-003 antibody Fab fragment reveals basis for lack of dipeptidase activity. J Struct Biol 2020; 211:107512. [DOI: 10.1016/j.jsb.2020.107512] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2020] [Revised: 04/10/2020] [Accepted: 04/17/2020] [Indexed: 01/30/2023]
|
14
|
Wiedemeyer WR, Bheddah S, Saechao C, French D, Huntzicker E, Kempema A, Gavrilyuk J, Liu D, Sisodiya V, He A, Zhang Z, Aujay MA, Hayashi K, Vivona S, Zhao X, Walter K, Saunders LR, Hampl J, Madhavan S, Pysz M, Bankovich AJ, Karsunky H, Dylla SJ. Abstract NT-113: SC-003, AN ANTIBODY-DRUG CONJUGATE TARGETING DIPEPTIDASE 3, EXHIBITS POTENT ANTI-TUMOR ACTIVITY IN PATIENT-DERIVED XENOGRAFT MODELS OF HIGH GRADE SEROUS OVARIAN CANCER. Clin Cancer Res 2019. [DOI: 10.1158/1557-3265.ovcasymp18-nt-113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Disclosures: All authors are employees of AbbVie. The design, study conduct, and financial support for this research were provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the publication.
Ovarian cancer describes a group of malignancies that remain a serious threat to women's health and claim more than 14,000 deaths in the US each year. Among these, high-grade serous ovarian cancers (HGSC) represent the most common and aggressive form, and tumor recurrence is near-universal following initial response to carboplatin and paclitaxel. While multiple treatment options are available for platinum-sensitive recurrent HGSC, such as continued use of carboplatin/paclitaxel with or without bevacizumab, as well as several FDA-approved PARP inhibitors, there are few effective treatment options for platinum-resistant HGSC. Its inherent heterogeneity, characterized by genomic instability and numerous DNA copy number aberrations, poses challenges to the discovery of novel therapeutic targets.
Patient-derived xenograft (PDX) models are an important platform for target identification and efficacy testing of therapeutic agents, as they sustain the intratumoral heterogeneity observed in advanced human tumors more faithfully than established cell lines. The isolation of distinct tumor cell populations by flow cytometry and subsequent testing of their tumorigenic potential can identify tumor-initiating cells (TICs), which have the potential to propagate the tumor over multiple generations in immune-deficient NOD/SCID mice. Thorough characterization of these TIC populations by transcriptome profiling and flow cytometry has identified TIC-enriched cell surface proteins that are targetable by antibody drug conjugates (ADCs), including EFNA4 in mixed Müllerian and ovarian cancers and PTK7 in triple-negative breast and ovarian cancers. ADCs consist of a monoclonal antibody directed against a cell surface epitope linked to a cytotoxic agent, such as auristatin, maytansinoid, or pyrrolobenzodiazepine (PBD).
Here, we describe the generation and characterization of a PDX bank for ovarian cancers that led to the identification of dipeptidase 3 (DPEP3) as a TIC-associated target in HGSC. We show that DPEP3 is enriched in the TIC fraction of platinum-sensitive and platinum-resistant HGSC PDX models, where it localizes to the plasma membrane and is detected by flow cytometry and immunohistochemistry (IHC). In contrast, DPEP3 expression is low or absent in most normal adult tissues, thus providing a therapeutic window for an antibody-based therapeutic agent. In order to target DPEP3-expressing ovarian cancer cells, we developed SC-003, an ADC consisting of a humanized monoclonal antibody linked to a PBD dimer via a cleavable linker. We show that SC-003 specifically binds to DPEP3-expressing cells and, upon internalization, elicits cytotoxicity via release of its PBD warhead following lysosomal degradation of the antibody component. A single dose of SC-003 induced tumor regression in DPEP3-positive HGSC PDX models, including platinum-resistant PDX models. Mechanistically, we show that the anti-tumor effect of SC-003 is mediated by a significant reduction in TIC frequency. Moreover, combination with an anti-PD1 antibody potentiated SC-003 efficacy in a syngeneic mouse model engineered to overexpress human DPEP3. In summary, these findings support the clinical development of SC-003 as a novel therapeutic agent for HGSC.
Citation Format: Wolf R. Wiedemeyer, Sheila Bheddah, Christine Saechao, Dorothy French, Erik Huntzicker, Aaron Kempema, Julia Gavrilyuk, David Liu, Vikram Sisodiya, Alina He, Zhaomei Zhang, Monette A. Aujay, Kristyn Hayashi, Sandro Vivona, Xi Zhao, Kimberly Walter, Laura R. Saunders, Johannes Hampl, Shravanthi Madhavan, Marybeth Pysz, Alexander J. Bankovich, Holger Karsunky, Scott J. Dylla. SC-003, AN ANTIBODY-DRUG CONJUGATE TARGETING DIPEPTIDASE 3, EXHIBITS POTENT ANTI-TUMOR ACTIVITY IN PATIENT-DERIVED XENOGRAFT MODELS OF HIGH GRADE SEROUS OVARIAN CANCER [abstract]. In: Proceedings of the 12th Biennial Ovarian Cancer Research Symposium; Sep 13-15, 2018; Seattle, WA. Philadelphia (PA): AACR; Clin Cancer Res 2019;25(22 Suppl):Abstract nr NT-113.
Collapse
Affiliation(s)
- Wolf R. Wiedemeyer
- AbbVie Stemcentrx LLC, 450 East Jamie Court, South San Francisco, CA 94080, USA
| | - Sheila Bheddah
- AbbVie Stemcentrx LLC, 450 East Jamie Court, South San Francisco, CA 94080, USA
| | - Christine Saechao
- AbbVie Stemcentrx LLC, 450 East Jamie Court, South San Francisco, CA 94080, USA
| | - Dorothy French
- AbbVie Stemcentrx LLC, 450 East Jamie Court, South San Francisco, CA 94080, USA
| | - Erik Huntzicker
- AbbVie Stemcentrx LLC, 450 East Jamie Court, South San Francisco, CA 94080, USA
| | - Aaron Kempema
- AbbVie Stemcentrx LLC, 450 East Jamie Court, South San Francisco, CA 94080, USA
| | - Julia Gavrilyuk
- AbbVie Stemcentrx LLC, 450 East Jamie Court, South San Francisco, CA 94080, USA
| | - David Liu
- AbbVie Stemcentrx LLC, 450 East Jamie Court, South San Francisco, CA 94080, USA
| | - Vikram Sisodiya
- AbbVie Stemcentrx LLC, 450 East Jamie Court, South San Francisco, CA 94080, USA
| | - Alina He
- AbbVie Stemcentrx LLC, 450 East Jamie Court, South San Francisco, CA 94080, USA
| | - Zhaomei Zhang
- AbbVie Stemcentrx LLC, 450 East Jamie Court, South San Francisco, CA 94080, USA
| | - Monette A. Aujay
- AbbVie Stemcentrx LLC, 450 East Jamie Court, South San Francisco, CA 94080, USA
| | - Kristyn Hayashi
- AbbVie Stemcentrx LLC, 450 East Jamie Court, South San Francisco, CA 94080, USA
| | - Sandro Vivona
- AbbVie Stemcentrx LLC, 450 East Jamie Court, South San Francisco, CA 94080, USA
| | - Xi Zhao
- AbbVie Stemcentrx LLC, 450 East Jamie Court, South San Francisco, CA 94080, USA
| | - Kimberly Walter
- AbbVie Stemcentrx LLC, 450 East Jamie Court, South San Francisco, CA 94080, USA
| | - Laura R. Saunders
- AbbVie Stemcentrx LLC, 450 East Jamie Court, South San Francisco, CA 94080, USA
| | - Johannes Hampl
- AbbVie Stemcentrx LLC, 450 East Jamie Court, South San Francisco, CA 94080, USA
| | - Shravanthi Madhavan
- AbbVie Stemcentrx LLC, 450 East Jamie Court, South San Francisco, CA 94080, USA
| | - Marybeth Pysz
- AbbVie Stemcentrx LLC, 450 East Jamie Court, South San Francisco, CA 94080, USA
| | | | - Holger Karsunky
- AbbVie Stemcentrx LLC, 450 East Jamie Court, South San Francisco, CA 94080, USA
| | - Scott J. Dylla
- AbbVie Stemcentrx LLC, 450 East Jamie Court, South San Francisco, CA 94080, USA
| |
Collapse
|
15
|
Ressl S, Vu BK, Vivona S, Martinelli DC, Südhof TC, Brunger AT. Structures of C1q-like proteins reveal unique features among the C1q/TNF superfamily. Structure 2015; 23:688-99. [PMID: 25752542 DOI: 10.1016/j.str.2015.01.019] [Citation(s) in RCA: 49] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2014] [Revised: 01/27/2015] [Accepted: 01/28/2015] [Indexed: 11/16/2022]
Abstract
C1q-like (C1QL) -1, -2, and -3 proteins are encoded by homologous genes that are highly expressed in brain. C1QLs bind to brain-specific angiogenesis inhibitor 3 (BAI3), an adhesion-type G-protein coupled receptor that may regulate dendritic morphology by organizing actin filaments. To begin to understand the function of C1QLs, we determined high-resolution crystal structures of the globular C1q-domains of C1QL1, C1QL2, and C1QL3. Each structure is a trimer, with each protomer forming a jelly-roll fold consisting of 10 β strands. Moreover, C1QL trimers may assemble into higher-order oligomers similar to adiponectin and contain four Ca(2+)-binding sites along the trimeric symmetry axis, as well as additional surface Ca(2+)-binding sites. Mutation of Ca(2+)-coordinating residues along the trimeric symmetry axis lowered the Ca(2+)-binding affinity and protein stability. Our results reveal unique structural features of C1QLs among C1q/TNF superfamily proteins that may be associated with their specific brain functions.
Collapse
Affiliation(s)
- Susanne Ressl
- Department of Molecular and Cellular Physiology, Stanford University, Stanford, CA 94305, USA.
| | - Brandon K Vu
- Department of Molecular and Cellular Physiology, Stanford University, Stanford, CA 94305, USA
| | - Sandro Vivona
- Department of Molecular and Cellular Physiology, Stanford University, Stanford, CA 94305, USA
| | - David C Martinelli
- Department of Molecular and Cellular Physiology, Stanford University, Stanford, CA 94305, USA
| | - Thomas C Südhof
- Department of Molecular and Cellular Physiology, Stanford University, Stanford, CA 94305, USA; Howard Hughes Medical Institute, Stanford, CA 94305, USA
| | - Axel T Brunger
- Department of Molecular and Cellular Physiology, Stanford University, Stanford, CA 94305, USA; Howard Hughes Medical Institute, Stanford, CA 94305, USA; Departments of Neurology and Neurological Sciences, Photon Science, and Structural Biology, Stanford University, Stanford, CA 94305, USA.
| |
Collapse
|
16
|
Zhang Y, Diao J, Colbert KN, Lai Y, Pfuetzner RA, Padolina MS, Vivona S, Ressl S, Cipriano DJ, Choi UB, Shah N, Weis WI, Brunger AT. Munc18a does not alter fusion rates mediated by neuronal SNAREs, synaptotagmin, and complexin. J Biol Chem 2015; 290:10518-34. [PMID: 25716318 PMCID: PMC4400359 DOI: 10.1074/jbc.m114.630772] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2014] [Indexed: 01/25/2023] Open
Abstract
Sec1/Munc18 (SM) proteins are essential for membrane trafficking, but their molecular mechanism remains unclear. Using a single vesicle-vesicle content-mixing assay with reconstituted neuronal SNAREs, synaptotagmin-1, and complexin-1, we show that the neuronal SM protein Munc18a/nSec1 has no effect on the intrinsic kinetics of both spontaneous fusion and Ca2+-triggered fusion between vesicles that mimic synaptic vesicles and the plasma membrane. However, wild type Munc18a reduced vesicle association ∼50% when the vesicles bearing the t-SNAREs syntaxin-1A and SNAP-25 were preincubated with Munc18 for 30 min. Single molecule experiments with labeled SNAP-25 indicate that the reduction of vesicle association is a consequence of sequestration of syntaxin-1A by Munc18a and subsequent release of SNAP-25 (i.e. Munc18a captures syntaxin-1A via its high affinity interaction). Moreover, a phosphorylation mimic mutant of Munc18a with reduced affinity to syntaxin-1A results in less reduction of vesicle association. In summary, Munc18a does not directly affect fusion, although it has an effect on the t-SNARE complex, depending on the presence of other factors and experimental conditions. Our results suggest that Munc18a primarily acts at the prefusion stage.
Collapse
Affiliation(s)
- Yunxiang Zhang
- From the Departments of Molecular and Cellular Physiology, Neurology and Neurological Sciences, Structural Biology, and Photon Science and
| | - Jiajie Diao
- From the Departments of Molecular and Cellular Physiology, Neurology and Neurological Sciences, Structural Biology, and Photon Science and the Howard Hughes Medical Institute, Stanford University, Stanford, California 94305
| | - Karen N Colbert
- From the Departments of Molecular and Cellular Physiology, Structural Biology, and
| | - Ying Lai
- From the Departments of Molecular and Cellular Physiology, Neurology and Neurological Sciences, Structural Biology, and Photon Science and
| | - Richard A Pfuetzner
- From the Departments of Molecular and Cellular Physiology, Neurology and Neurological Sciences, Structural Biology, and Photon Science and the Howard Hughes Medical Institute, Stanford University, Stanford, California 94305
| | - Mark S Padolina
- From the Departments of Molecular and Cellular Physiology, Neurology and Neurological Sciences, Structural Biology, and Photon Science and the Howard Hughes Medical Institute, Stanford University, Stanford, California 94305
| | - Sandro Vivona
- From the Departments of Molecular and Cellular Physiology, Neurology and Neurological Sciences, Structural Biology, and Photon Science and
| | - Susanne Ressl
- From the Departments of Molecular and Cellular Physiology, Neurology and Neurological Sciences, Structural Biology, and Photon Science and
| | - Daniel J Cipriano
- From the Departments of Molecular and Cellular Physiology, Neurology and Neurological Sciences, Structural Biology, and Photon Science and the Howard Hughes Medical Institute, Stanford University, Stanford, California 94305
| | - Ucheor B Choi
- From the Departments of Molecular and Cellular Physiology, Neurology and Neurological Sciences, Structural Biology, and Photon Science and the Howard Hughes Medical Institute, Stanford University, Stanford, California 94305
| | | | - William I Weis
- From the Departments of Molecular and Cellular Physiology, Structural Biology, and Photon Science and
| | - Axel T Brunger
- From the Departments of Molecular and Cellular Physiology, Neurology and Neurological Sciences, Structural Biology, and Photon Science and the Howard Hughes Medical Institute, Stanford University, Stanford, California 94305
| |
Collapse
|
17
|
Diao J, Liu R, Rong Y, Zhao M, Zhang J, Lai Y, Zhou Q, Wilz LM, Li J, Vivona S, Pfuetzner RA, Brunger AT, Zhong Q. ATG14 promotes membrane tethering and fusion of autophagosomes to endolysosomes. Nature 2015; 520:563-6. [PMID: 25686604 DOI: 10.1038/nature14147] [Citation(s) in RCA: 415] [Impact Index Per Article: 46.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2014] [Accepted: 12/08/2014] [Indexed: 01/09/2023]
Abstract
Autophagy, an important catabolic pathway implicated in a broad spectrum of human diseases, begins by forming double membrane autophagosomes that engulf cytosolic cargo and ends by fusing autophagosomes with lysosomes for degradation. Membrane fusion activity is required for early biogenesis of autophagosomes and late degradation in lysosomes. However, the key regulatory mechanisms of autophagic membrane tethering and fusion remain largely unknown. Here we report that ATG14 (also known as beclin-1-associated autophagy-related key regulator (Barkor) or ATG14L), an essential autophagy-specific regulator of the class III phosphatidylinositol 3-kinase complex, promotes membrane tethering of protein-free liposomes, and enhances hemifusion and full fusion of proteoliposomes reconstituted with the target (t)-SNAREs (soluble N-ethylmaleimide-sensitive factor attachment protein receptors) syntaxin 17 (STX17) and SNAP29, and the vesicle (v)-SNARE VAMP8 (vesicle-associated membrane protein 8). ATG14 binds to the SNARE core domain of STX17 through its coiled-coil domain, and stabilizes the STX17-SNAP29 binary t-SNARE complex on autophagosomes. The STX17 binding, membrane tethering and fusion-enhancing activities of ATG14 require its homo-oligomerization by cysteine repeats. In ATG14 homo-oligomerization-defective cells, autophagosomes still efficiently form but their fusion with endolysosomes is blocked. Recombinant ATG14 homo-oligomerization mutants also completely lose their ability to promote membrane tethering and to enhance SNARE-mediated fusion in vitro. Taken together, our data suggest an autophagy-specific membrane fusion mechanism in which oligomeric ATG14 directly binds to STX17-SNAP29 binary t-SNARE complex on autophagosomes and primes it for VAMP8 interaction to promote autophagosome-endolysosome fusion.
Collapse
Affiliation(s)
- Jiajie Diao
- 1] Department of Molecular and Cellular Physiology, Stanford University, Stanford, California 94305, USA [2] Department of Structural Biology, Stanford University, Stanford, California 94305, USA [3] Department of Photon Science, Stanford University, Stanford, California 94305, USA [4] Department of Neurology and Neurological Sciences, Stanford University, Stanford, California 94305, USA [5] Howard Hughes Medical Institute, Stanford University, Stanford, California 94305, USA
| | - Rong Liu
- 1] Center for Autophagy Research, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA [2] Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA [3] College of Food Science &Nutritional Engineering, China Agricultural University, Beijing 100083, China
| | - Yueguang Rong
- 1] Center for Autophagy Research, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA [2] Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA
| | - Minglei Zhao
- 1] Department of Molecular and Cellular Physiology, Stanford University, Stanford, California 94305, USA [2] Department of Structural Biology, Stanford University, Stanford, California 94305, USA [3] Department of Photon Science, Stanford University, Stanford, California 94305, USA [4] Department of Neurology and Neurological Sciences, Stanford University, Stanford, California 94305, USA [5] Howard Hughes Medical Institute, Stanford University, Stanford, California 94305, USA
| | - Jing Zhang
- 1] Center for Autophagy Research, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA [2] Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA
| | - Ying Lai
- 1] Department of Molecular and Cellular Physiology, Stanford University, Stanford, California 94305, USA [2] Department of Structural Biology, Stanford University, Stanford, California 94305, USA [3] Department of Photon Science, Stanford University, Stanford, California 94305, USA [4] Department of Neurology and Neurological Sciences, Stanford University, Stanford, California 94305, USA [5] Howard Hughes Medical Institute, Stanford University, Stanford, California 94305, USA
| | - Qiangjun Zhou
- 1] Department of Molecular and Cellular Physiology, Stanford University, Stanford, California 94305, USA [2] Department of Structural Biology, Stanford University, Stanford, California 94305, USA [3] Department of Photon Science, Stanford University, Stanford, California 94305, USA [4] Department of Neurology and Neurological Sciences, Stanford University, Stanford, California 94305, USA [5] Howard Hughes Medical Institute, Stanford University, Stanford, California 94305, USA
| | - Livia M Wilz
- Division of Biochemistry, Biophysics and Structural Biology, Department of Molecular and Cell Biology, University of California at Berkeley, Berkeley, California 94720, USA
| | - Jianxu Li
- Division of Biochemistry, Biophysics and Structural Biology, Department of Molecular and Cell Biology, University of California at Berkeley, Berkeley, California 94720, USA
| | - Sandro Vivona
- 1] Department of Molecular and Cellular Physiology, Stanford University, Stanford, California 94305, USA [2] Department of Structural Biology, Stanford University, Stanford, California 94305, USA [3] Department of Photon Science, Stanford University, Stanford, California 94305, USA [4] Department of Neurology and Neurological Sciences, Stanford University, Stanford, California 94305, USA [5] Howard Hughes Medical Institute, Stanford University, Stanford, California 94305, USA
| | - Richard A Pfuetzner
- 1] Department of Molecular and Cellular Physiology, Stanford University, Stanford, California 94305, USA [2] Department of Structural Biology, Stanford University, Stanford, California 94305, USA [3] Department of Photon Science, Stanford University, Stanford, California 94305, USA [4] Department of Neurology and Neurological Sciences, Stanford University, Stanford, California 94305, USA [5] Howard Hughes Medical Institute, Stanford University, Stanford, California 94305, USA
| | - Axel T Brunger
- 1] Department of Molecular and Cellular Physiology, Stanford University, Stanford, California 94305, USA [2] Department of Structural Biology, Stanford University, Stanford, California 94305, USA [3] Department of Photon Science, Stanford University, Stanford, California 94305, USA [4] Department of Neurology and Neurological Sciences, Stanford University, Stanford, California 94305, USA [5] Howard Hughes Medical Institute, Stanford University, Stanford, California 94305, USA
| | - Qing Zhong
- 1] Center for Autophagy Research, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA [2] Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA
| |
Collapse
|
18
|
Zhao M, Wu S, Zhou Q, Vivona S, Cipriano DJ, Cheng Y, Brunger AT. Mechanistic insights into the recycling machine of the SNARE complex. Nature 2015; 518:61-7. [PMID: 25581794 PMCID: PMC4320033 DOI: 10.1038/nature14148] [Citation(s) in RCA: 190] [Impact Index Per Article: 21.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2014] [Accepted: 12/10/2014] [Indexed: 12/11/2022]
Abstract
Evolutionarily conserved SNARE (soluble N-ethylmaleimide sensitive factor attachment protein receptors) proteins form a complex that drives membrane fusion in eukaryotes. The ATPase NSF (N-ethylmaleimide sensitive factor), together with SNAPs (soluble NSF attachment protein), disassembles the SNARE complex into its protein components, making individual SNAREs available for subsequent rounds of fusion. Here we report structures of ATP- and ADP-bound NSF, and the NSF/SNAP/SNARE (20S) supercomplex determined by single-particle electron cryomicroscopy at near-atomic to sub-nanometre resolution without imposing symmetry. Large, potentially force-generating, conformational differences exist between ATP- and ADP-bound NSF. The 20S supercomplex exhibits broken symmetry, transitioning from six-fold symmetry of the NSF ATPase domains to pseudo four-fold symmetry of the SNARE complex. SNAPs interact with the SNARE complex with an opposite structural twist, suggesting an unwinding mechanism. The interfaces between NSF, SNAPs, and SNAREs exhibit characteristic electrostatic patterns, suggesting how one NSF/SNAP species can act on many different SNARE complexes.
Collapse
Affiliation(s)
- Minglei Zhao
- Department of Molecular and Cellular Physiology, Howard Hughes Medical Institute, Stanford University, Stanford, California 94305, USA
| | - Shenping Wu
- Keck Advanced Microscopy Laboratory, Department of Biochemistry and Biophysics, University of California, San Francisco, California 94158, USA
| | - Qiangjun Zhou
- Department of Molecular and Cellular Physiology, Howard Hughes Medical Institute, Stanford University, Stanford, California 94305, USA
| | - Sandro Vivona
- Department of Molecular and Cellular Physiology, Howard Hughes Medical Institute, Stanford University, Stanford, California 94305, USA
| | - Daniel J Cipriano
- Department of Molecular and Cellular Physiology, Howard Hughes Medical Institute, Stanford University, Stanford, California 94305, USA
| | - Yifan Cheng
- Keck Advanced Microscopy Laboratory, Department of Biochemistry and Biophysics, University of California, San Francisco, California 94158, USA
| | - Axel T Brunger
- 1] Department of Molecular and Cellular Physiology, Howard Hughes Medical Institute, Stanford University, Stanford, California 94305, USA [2] Department of Neurology and Neurological Sciences, Department of Structural Biology, Department of Photon Science, Stanford University, Stanford, California 94305, USA
| |
Collapse
|
19
|
Vivona S, Cipriano DJ, O'Leary S, Li YH, Fenn TD, Brunger AT. Disassembly of all SNARE complexes by N-ethylmaleimide-sensitive factor (NSF) is initiated by a conserved 1:1 interaction between α-soluble NSF attachment protein (SNAP) and SNARE complex. J Biol Chem 2013; 288:24984-91. [PMID: 23836889 PMCID: PMC3750193 DOI: 10.1074/jbc.m113.489807] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
Abstract
Vesicle trafficking in eukaryotic cells is facilitated by SNARE-mediated membrane fusion. The ATPase NSF (N-ethylmaleimide-sensitive factor) and the adaptor protein α-SNAP (soluble NSF attachment protein) disassemble all SNARE complexes formed throughout different pathways, but the effect of SNARE sequence and domain variation on the poorly understood disassembly mechanism is unknown. By measuring SNARE-stimulated ATP hydrolysis rates, Michaelis-Menten constants for disassembly, and SNAP-SNARE binding constants for four different ternary SNARE complexes and one binary complex, we found a conserved mechanism, not influenced by N-terminal SNARE domains. α-SNAP and the ternary SNARE complex form a 1:1 complex as revealed by multiangle light scattering. We propose a model of NSF-mediated disassembly in which the reaction is initiated by a 1:1 interaction between α-SNAP and the ternary SNARE complex, followed by NSF binding. Subsequent additional α-SNAP binding events may occur as part of a processive disassembly mechanism.
Collapse
Affiliation(s)
- Sandro Vivona
- Department of Molecular and Cellular Physiology, Stanford University Medical School, Stanford, California 94305, USA
| | | | | | | | | | | |
Collapse
|
20
|
Burré J, Vivona S, Diao J, Sharma M, Brunger AT, Südhof TC. Properties of native brain α-synuclein. Nature 2013; 498:E4-6; discussion E6-7. [PMID: 23765500 PMCID: PMC4255827 DOI: 10.1038/nature12125] [Citation(s) in RCA: 242] [Impact Index Per Article: 22.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2012] [Accepted: 03/28/2013] [Indexed: 12/19/2022]
Affiliation(s)
- Jacqueline Burré
- Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, California 94305, USA
| | | | | | | | | | | |
Collapse
|
21
|
Cipriano DJ, Jung J, Vivona S, Fenn TD, Brunger AT, Bryant Z. Processive ATP-driven substrate disassembly by the N-ethylmaleimide-sensitive factor (NSF) molecular machine. J Biol Chem 2013; 288:23436-45. [PMID: 23775070 PMCID: PMC4520572 DOI: 10.1074/jbc.m113.476705] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Abstract
SNARE proteins promote membrane fusion by forming a four-stranded parallel helical bundle that brings the membranes into close proximity. Post-fusion, the complex is disassembled by an AAA+ ATPase called N-ethylmaleimide-sensitive factor (NSF). We present evidence that NSF uses a processive unwinding mechanism to disassemble SNARE proteins. Using a real-time disassembly assay based on fluorescence dequenching, we correlate NSF-driven disassembly rates with the SNARE-activated ATPase activity of NSF. Neuronal SNAREs activate the ATPase rate of NSF by ∼26-fold. One SNARE complex takes an average of ∼5 s to disassemble in a process that consumes ∼50 ATP. Investigations of substrate requirements show that NSF is capable of disassembling a truncated SNARE substrate consisting of only the core SNARE domain, but not an unrelated four-stranded coiled-coil. NSF can also disassemble an engineered double-length SNARE complex, suggesting a processive unwinding mechanism. We further investigated processivity using single-turnover experiments, which show that SNAREs can be unwound in a single encounter with NSF. We propose a processive helicase-like mechanism for NSF in which ∼1 residue is unwound for every hydrolyzed ATP molecule.
Collapse
Affiliation(s)
- Daniel J Cipriano
- Department of Molecular and Cellular Physiology, Stanford University, Stanford, California 94305, USA
| | | | | | | | | | | |
Collapse
|
22
|
Diao J, Burré J, Vivona S, Cipriano DJ, Sharma M, Kyoung M, Südhof TC, Brunger AT. Native α-synuclein induces clustering of synaptic-vesicle mimics via binding to phospholipids and synaptobrevin-2/VAMP2. eLife 2013; 2:e00592. [PMID: 23638301 PMCID: PMC3639508 DOI: 10.7554/elife.00592] [Citation(s) in RCA: 234] [Impact Index Per Article: 21.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2013] [Accepted: 03/25/2013] [Indexed: 12/13/2022] Open
Abstract
α-Synuclein is a presynaptic protein that is implicated in Parkinson's and other neurodegenerative diseases. Physiologically, native α-synuclein promotes presynaptic SNARE-complex assembly, but its molecular mechanism of action remains unknown. Here, we found that native α-synuclein promotes clustering of synaptic-vesicle mimics, using a single-vesicle optical microscopy system. This vesicle-clustering activity was observed for both recombinant and native α-synuclein purified from mouse brain. Clustering was dependent on specific interactions of native α-synuclein with both synaptobrevin-2/VAMP2 and anionic lipids. Out of the three familial Parkinson's disease-related point mutants of α-synuclein, only the lipid-binding deficient mutation A30P disrupted clustering, hinting at a possible loss of function phenotype for this mutant. α-Synuclein had little effect on Ca(2+)-triggered fusion in our reconstituted single-vesicle system, consistent with in vivo data. α-Synuclein may therefore lead to accumulation of synaptic vesicles at the active zone, providing a 'buffer' of synaptic vesicles, without affecting neurotransmitter release itself. DOI:http://dx.doi.org/10.7554/eLife.00592.001.
Collapse
Affiliation(s)
- Jiajie Diao
- Department of Molecular and Cellular Physiology, Stanford University, Stanford, United States
- Department of Structural Biology, Stanford University, Stanford, United States
- Departments of Photon Sciences, and Neurology and Neurological Sciences, Stanford University, Stanford, United States
- Howard Hughes Medical Institute, Stanford University, Stanford, United States
| | - Jacqueline Burré
- Department of Molecular and Cellular Physiology, Stanford University, Stanford, United States
| | - Sandro Vivona
- Department of Molecular and Cellular Physiology, Stanford University, Stanford, United States
- Department of Structural Biology, Stanford University, Stanford, United States
- Departments of Photon Sciences, and Neurology and Neurological Sciences, Stanford University, Stanford, United States
- Howard Hughes Medical Institute, Stanford University, Stanford, United States
| | - Daniel J Cipriano
- Department of Molecular and Cellular Physiology, Stanford University, Stanford, United States
- Department of Structural Biology, Stanford University, Stanford, United States
- Departments of Photon Sciences, and Neurology and Neurological Sciences, Stanford University, Stanford, United States
- Howard Hughes Medical Institute, Stanford University, Stanford, United States
| | - Manu Sharma
- Department of Molecular and Cellular Physiology, Stanford University, Stanford, United States
| | - Minjoung Kyoung
- Department of Molecular and Cellular Physiology, Stanford University, Stanford, United States
- Department of Structural Biology, Stanford University, Stanford, United States
- Departments of Photon Sciences, and Neurology and Neurological Sciences, Stanford University, Stanford, United States
- Howard Hughes Medical Institute, Stanford University, Stanford, United States
| | - Thomas C Südhof
- Department of Molecular and Cellular Physiology, Stanford University, Stanford, United States
- Howard Hughes Medical Institute, Stanford University, Stanford, United States
- For correspondence: (TCS)
| | - Axel T Brunger
- Department of Molecular and Cellular Physiology, Stanford University, Stanford, United States
- Department of Structural Biology, Stanford University, Stanford, United States
- Departments of Photon Sciences, and Neurology and Neurological Sciences, Stanford University, Stanford, United States
- Howard Hughes Medical Institute, Stanford University, Stanford, United States
- For correspondence: (ATB)
| |
Collapse
|
23
|
Bowman BN, McAdam PR, Vivona S, Zhang JX, Luong T, Belew RK, Sahota H, Guiney D, Valafar F, Fierer J, Woelk CH. Improving reverse vaccinology with a machine learning approach. Vaccine 2011; 29:8156-64. [PMID: 21864619 DOI: 10.1016/j.vaccine.2011.07.142] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2011] [Revised: 07/19/2011] [Accepted: 07/28/2011] [Indexed: 11/27/2022]
Abstract
Reverse vaccinology aims to accelerate subunit vaccine design by rapidly predicting which proteins in a pathogenic bacterial proteome are putative protective antigens. Support vector machine classification is a machine learning approach that has been applied to solve numerous classification problems in biological sciences but has not previously been incorporated into a reverse vaccinology approach. A training data set of 136 bacterial protective antigens paired with 136 non-antigens was constructed and bioinformatic tools were used to annotate this data for predicted protein features, many of which are associated with antigenicity (i.e. extracellular localization, signal peptides and B-cell epitopes). Annotation was used to train support vector machine classifiers that exhibited a maximum accuracy of 92% for discriminating protective antigens from non-antigens as assessed by a leave-tenth-out cross-validation approach. These accuracies were superior to those achieved when annotating training data with auto and cross covariance transformations of z-descriptors for hydrophobicity, molecular size and polarity, or when classification was performed using regression methods. To further validate support vector machine classifiers, they were used to rank all the proteins in six bacterial proteomes for their antigenicity. Protective antigens from the training data were significantly recalled (enriched) in the top 75 ranked proteins for all six proteomes as assessed by a Fisher's exact test (p<0.05). This paper describes a superior workflow for performing reverse vaccinology studies and provides a benchmark training data set that can be used to evaluate future methodological improvements.
Collapse
Affiliation(s)
- Brett N Bowman
- Bioinformatics and Medical Informatics, San Diego State University, San Diego, CA 92182, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Abstract
SNARE protein complexes are key mediators of exocytosis by juxtaposing opposing membranes, leading to membrane fusion. SNAREs generally consist of one or two core domains that can form a four-helix bundle with other SNARE core domains. Some SNAREs, such as syntaxin target-SNAREs and longin vesicular-SNAREs, have independent, folded N-terminal domains that can interact with their respective SNARE core domains and thereby affect the kinetics of SNARE complex formation. This autoinhibition mechanism is believed to regulate the role of the longin VAMP7/TI-VAMP in neuronal morphogenesis. Here we use nuclear magnetic resonance spectroscopy to study the longin-SNARE core domain interaction for VAMP7. Using complete backbone resonance assignments, chemical shift perturbations analysis, and hydrogen/deuterium exchange experiments, we conclusively show that VAMP7 adopts a preferentially closed conformation in solution. Taken together, the closed conformation of longins is conserved, in contrast to the syntaxin family of SNAREs for which mixtures of open and closed states have been observed. This may indicate different regulatory mechanisms for SNARE complexes containing syntaxins and longins, respectively.
Collapse
Affiliation(s)
- Sandro Vivona
- Department of Molecular and Cellular Physiology, Stanford University, Stanford, California 94305, USA
| | | | | | | | | | | |
Collapse
|
25
|
Vivona S, Gardy JL, Ramachandran S, Brinkman FSL, Raghava GPS, Flower DR, Filippini F. Computer-aided biotechnology: from immuno-informatics to reverse vaccinology. Trends Biotechnol 2008; 26:190-200. [PMID: 18291542 DOI: 10.1016/j.tibtech.2007.12.006] [Citation(s) in RCA: 75] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2007] [Revised: 12/06/2007] [Accepted: 12/19/2007] [Indexed: 11/18/2022]
Abstract
Genome sequences from many organisms, including humans, have been completed, and high-throughput analyses have produced burgeoning volumes of 'omics' data. Bioinformatics is crucial for the management and analysis of such data and is increasingly used to accelerate progress in a wide variety of large-scale and object-specific functional analyses. Refined algorithms enable biotechnologists to follow 'computer-aided strategies' based on experiments driven by high-confidence predictions. In order to address compound problems, current efforts in immuno-informatics and reverse vaccinology are aimed at developing and tuning integrative approaches and user-friendly, automated bioinformatics environments. This will herald a move to 'computer-aided biotechnology': smart projects in which time-consuming and expensive large-scale experimental approaches are progressively replaced by prediction-driven investigations.
Collapse
Affiliation(s)
- Sandro Vivona
- Molecular Biology and Bioinformatics Unit, Department of Biology, University of Padua, Padua, Italy
| | | | | | | | | | | | | |
Collapse
|
26
|
Abstract
Background Since a milestone work on Neisseria meningitidis B, Reverse Vaccinology has strongly enhanced the identification of vaccine candidates by replacing several experimental tasks using in silico prediction steps. These steps have allowed scientists to face the selection of antigens from the predicted proteome of pathogens, for which cell culture is difficult or impossible, saving time and money. However, this good example of bioinformatics-driven immunology can be further developed by improving in silico steps and implementing biologist-friendly tools. Results We introduce NERVE (New Enhanced Reverse Vaccinology Environment), an user-friendly software environment for the in silico identification of the best vaccine candidates from whole proteomes of bacterial pathogens. The software integrates multiple robust and well-known algorithms for protein analysis and comparison. Vaccine candidates are ranked and presented in a html table showing relevant information and links to corresponding primary data. Information concerning all proteins of the analyzed proteome is not deleted along selection steps but rather flows into an SQL database for further mining and analyses. Conclusion After learning from recent years' works in this field and analysing a large dataset, NERVE has been implemented and tuned as the first available tool able to rank a restricted pool (~8–9% of the whole proteome) of vaccine candidates and to show high recall (~75–80%) of known protective antigens. These vaccine candidates are required to be "safe" (taking into account autoimmunity risk) and "easy" for further experimental, high-throughput screening (avoiding possibly not soluble antigens). NERVE is expected to help save time and money in vaccine design and is available as an additional file with this manuscript; updated versions will be available at .
Collapse
Affiliation(s)
- Sandro Vivona
- Molecular Biology and Bioinformatics (MOLBINFO), Department of Biology, University of Padua, viale G. Colombo 3, 35131 Padova, Italy
| | - Filippo Bernante
- Molecular Biology and Bioinformatics (MOLBINFO), Department of Biology, University of Padua, viale G. Colombo 3, 35131 Padova, Italy
| | - Francesco Filippini
- Molecular Biology and Bioinformatics (MOLBINFO), Department of Biology, University of Padua, viale G. Colombo 3, 35131 Padova, Italy
| |
Collapse
|
27
|
Do-Van-Quy D, Muschel LH, Vivona S. Follow-up of American Cancer Society Special Postdoctoral Research Fellowship recipients. Cancer Res 1976; 36:4702-4. [PMID: 1000511] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
A follow-up study of the 44 recipients of American Cancer Society, Inc., Special Postdoctoral Research Fellowship from 1962 to 1973 revealed that 11 of 21 M.D. candidates obtained their second (Ph.D.) degree at the end of training. By contrast, all but one among the 23 Ph.D. candidates were awarded the second (M.D.) degree. A great majority of either group remain in active research, regardless of whether or not they obtained the second degree. A very high percentage of their research is cancer related.
Collapse
|
28
|
Vivona S, Do-Van-Quy D, Wasserman I. Follow-up of American Cancer Society postdoctoral fellowship and faculty research award applicants. Cancer Res 1973; 33:3043-6. [PMID: 4748452] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
|
29
|
Vivona S, Do van Quy D. Comparability of the American Cancer Society and National Institutes of Health peer review systems. Cancer Res 1973; 33:919. [PMID: 4739656] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
|
30
|
Beebe GW, Simon AH, Vivona S. Long-term mortality follow-up of Army recruits who received adjuvant influenza virus vaccine in 1951-1953. Am J Epidemiol 1972; 95:337-46. [PMID: 5015584 DOI: 10.1093/oxfordjournals.aje.a121402] [Citation(s) in RCA: 46] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
|
31
|
Cavanaugh DC, Dangerfield HG, Hunter DH, Joy RJ, Marshall JD, Quy DV, Vivona S, Winter PE. Some observations on the current plague outbreak in the Republic of Vietnam. Am J Public Health Nations Health 1968; 58:742-52. [PMID: 5689324 PMCID: PMC1228386 DOI: 10.2105/ajph.58.4.742] [Citation(s) in RCA: 41] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
|
32
|
Russell PK, Nisalak A, Sukhavachana P, Vivona S. A plaque reduction test for dengue virus neutralizing antibodies. J Immunol 1967; 99:285-90. [PMID: 6031202] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
|
33
|
Cavanaugh DC, Vivona S, Gibson FL, Deuber GL, Rust JH. A transport medium for specimens containing Pasteurella pestis. Bull World Health Organ 1967; 37:455-60. [PMID: 5301387 PMCID: PMC2554271] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023] Open
Abstract
A medium, originally designed by Stuart and co-workers and later modified by Cary & Blair, for the maintenance and transport, without multiplication, of pathogenic bacteria contained in bacteriological specimens was tested in the laboratory and in the field in Viet-Nam to determine its effectiveness in preserving specimens known to contain Pasteurella pestis.The results indicate that this medium should be useful in diagnostic plague studies in areas where transport facilities are inadequate. Properly collected clinical specimens, sent to a central laboratory by any means and under any climatic conditions likely to be encountered in the hot tropics, should yield viable Pasteurella pestis for at least 30 days.
Collapse
|
34
|
Vivona S, Minh Ha TT, Gibson FL, Cavanaugh DC. Antibiotic sensitivities of Enterobacteriaceae isolated in Vietnam. Mil Med 1966; 131:68-71. [PMID: 4954878] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
|